Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries for ion channels.


 

Fig. 1. The screening workflow of Receptor.AI

The method involves in-depth molecular simulations of the ion channel in its native membrane environment, including its open, closed, and inactivated states, along with ensemble virtual screening that focuses on conformational mobility for each state. Tentative binding pockets are identified inside the pore, in the gating area, and at allosteric sites to address every conceivable mechanism of action.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9NY72

UPID:
SCN3B_HUMAN

ALTERNATIVE NAMES:
-

ALTERNATIVE UPACC:
Q9NY72; A5H1I5; Q17RL3; Q9ULR2

BACKGROUND:
The Sodium channel subunit beta-3 is essential for the unique persistent sodium currents and slower inactivation of sodium channel openings compared to the beta-1 subunit. Its interaction with NFASC suggests a pivotal role in axonal development and maintenance, specifically at the nodes of Ranvier.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Sodium channel subunit beta-3 could open doors to potential therapeutic strategies for addressing Brugada syndrome 7 and familial atrial fibrillation 16, diseases marked by severe cardiac rhythm abnormalities.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.